Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally.

CONTEXT The United Nations Millennium Development Goals (MDGs) are stimulating more rigorous evaluations of the impact of DOTS (the WHO-recommended approach to tuberculosis control based on 5 essential elements) and other possible strategies for tuberculosis (TB) control. OBJECTIVE To evaluate the prospects for detecting 70% of new sputum smear-positive cases and successfully treating 85% of these by the end of 2005, for reducing TB incidence, and for halving TB prevalence and deaths globally between 1990 and 2015, as specified by the MDGs. DATA SOURCES TB case notifications (1980-2003) from DOTS and non-DOTS programs and cohort treatment outcomes (1994-2002) reported annually to the World Health Organization (WHO) by up to 200 countries, TB death registrations, and prevalence surveys of infection and disease. STUDY SELECTION Case notification series that reflect trends in incidence, treatment outcomes from DOTS cohorts, death statistics from countries with WHO-validated vital registration systems, and national prevalence surveys of infection and disease. DATA EXTRACTION Case reports, treatment outcomes, prevalence surveys, and death registrations from WHO's global TB database covering 1990-2003 to estimate TB incidence, prevalence, and death rates through 2015 for 9 epidemiologically different world regions. DATA SYNTHESIS TB incidence increased globally in 2003, but incidence, prevalence, and death rates were approximately stable or decreased in 7 of 9 regions. The exceptions were regions of Africa with low (<4% in adults 15-49 years) and high rates (> or =4%) of HIV infection. The global detection rate of new smear-positive cases by DOTS programs increased from 11% in 1995 to 45% in 2003 (with the lowest case-detection rates in Eastern Europe and the highest rates in the Western Pacific) and could reach 60% by 2005. More than 17 million patients were treated in DOTS programs between 1994 and 2003, with overall treatment success rates more than 80% since 1998. In 2003, overall reported treatment success was 82%, with much variation among regions. The highest rates were reported in the Western Pacific region (89%) and lowest rates in African countries with high and low HIV infection rates (71% and 74%, respectively), in established market economies (77%), and in Eastern Europe (75%). To halve the prevalence rate by 2015, TB control programs must reach global targets for detection (70%) and treatment success (85%) and also reduce the incidence rate by at least 2% annually. To halve the death rate, incidence must decrease more steeply, by at least 5% to 6% annually. CONCLUSION Reduction of TB incidence, prevalence, and deaths by 2015 could be achieved in most of the world, but the challenge will be greatest in Africa and Eastern Europe.

[1]  John L. Johnson,et al.  Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults , 2001, AIDS.

[2]  Jaap Broekmans,et al.  Investing in strategies to reverse the global incidence of TB , 2005 .

[3]  P. Garner,et al.  Directly observed therapy for treating tuberculosis. , 2015, The Cochrane database of systematic reviews.

[4]  A. Khomenko,et al.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.

[5]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[6]  H. Rieder,et al.  Epidemiologic basis of tuberculosis control , 1999 .

[7]  R. Hayes,et al.  Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. , 2004, American journal of respiratory and critical care medicine.

[8]  Shenglan Tang,et al.  The effect of tuberculosis control in China. Comment , 2004 .

[9]  W. Lew,et al.  Incidence of pulmonary tuberculosis in Korean civil servants. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  Christopher Dye,et al.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.

[11]  A. Harries,et al.  Interim policy on collaborative TB / HIV activities. , 2004 .

[12]  P. Garner,et al.  Directly observed therapy for treating tuberculosis. , 2003, The Cochrane database of systematic reviews.

[13]  S M Blower,et al.  Potential impact of tuberculosis vaccines as epidemic control agents. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[15]  G W Comstock,et al.  Epidemiology of tuberculosis. , 1982, The American review of respiratory disease.

[16]  L. Krilov,et al.  Developing Infectious Disease Strategies for the Developing World , 2006, Annual Reports in Medicinal Chemistry.

[17]  T. Frieden,et al.  Trends in the prevalence and incidence of tuberculosis in south India. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  Brian G. Williams,et al.  Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS , 2003, Science.

[19]  C. Dye,et al.  The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. , 2001, The Journal of infectious diseases.

[20]  H. Barnum Cost savings from alternative treatments for tuberculosis. , 1986, Social science & medicine.

[21]  A. Harries,et al.  Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of Malawi. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  R. Chaisson,et al.  Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? , 2003, AIDS.

[23]  D. Fuchs,et al.  Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults , 2001, AIDS.

[24]  Christopher Dye,et al.  Prospects for worldwide tuberculosis control under the WHO DOTS strategy , 1998, The Lancet.

[25]  C. Murray,et al.  Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries , 1991, The Lancet.

[26]  A. Harries,et al.  Design of regimens for treating tuberculosis in patients with HIV infection, with particular reference to sub-Saharan Africa. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[27]  K. Floyd,et al.  Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. , 2002, Bulletin of the World Health Organization.

[28]  C. Dye,et al.  Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru , 2002, The Lancet.

[29]  Donna Neuberg,et al.  Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. , 2003, The New England journal of medicine.

[30]  D. Jamison,et al.  Disease Control Priorities in Developing Countries , 1993 .

[31]  D. McFarland,et al.  Preventive chemotherapy for HIV‐associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre , 1995, AIDS.

[32]  D. Maher,et al.  Scale up: meeting targets in global tuberculosis control , 2004, The Lancet.

[33]  Antonio Pio,et al.  Toman's tuberculosis: case detection, treatment, and monitoring. , 2005 .

[34]  Dean T. Jamison,et al.  World development report 1993 : investing in health , 1993 .

[35]  K. Stýblo The impact of HIV infection on the global epidemiology of tuberculosis. , 1991, Bulletin of the International Union against Tuberculosis and Lung Disease.

[36]  Christopher Dye,et al.  Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country , 1999 .

[37]  P. Garner,et al.  Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment , 1997, BMJ.

[38]  Borgdorff UvA-DARE ( Digital Academic Repository ) New measurable indicator for tuberculosis case detection , 2004 .

[39]  Lung Disease Revised international definitions in tuberculosis control. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[40]  P. Garner,et al.  Directly observed therapy , 1997, The Lancet.

[41]  S. Blower,et al.  The intrinsic transmission dynamics of tuberculosis epidemics , 1995, Nature Medicine.